The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
about
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practiceCardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGlucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studiesLEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular eventsComparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy usersComplex temporal topic evolution modelling using the Kullback-Leibler divergence and the Bhattacharyya distanceIncretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.Mechanisms for the cardiovascular effects of glucagon-like peptide-1.An overview of new GLP-1 receptor agonists for type 2 diabetes.Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.Cardiovascular safety and benefits of GLP-1 receptor agonists.Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).Cardiovascular safety of insulin: Between real-world data and reality.Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.
P2860
Q26741860-09A75070-0F63-4A14-ACFD-F1C64DC6A82CQ26749495-02EF6BE0-E0AD-4C1F-9E72-FC1A86E2E9B1Q28067465-B80FBE32-3BA1-4828-A524-9715BDECA8B2Q28079849-10835644-10B7-4191-BFAF-3F1EDDD670C2Q31044140-049C8A44-76B5-4CD0-AFC8-0843F398C534Q35709661-3D5732A0-5BD1-43C2-A46E-D569CFADFBD8Q36611527-B0186047-A42E-43A0-B808-92D0C3310FAAQ37077942-0A6D20E4-06BB-451C-8E69-33E793EFDC58Q37298012-21E0FEAB-9EE3-4376-A1CF-D90A7F4375A2Q37676824-19890138-070E-4344-A871-0E6A9D785F4CQ38589032-D66D3F3F-E75D-40E5-BC3F-210D27A943C9Q38639922-4CA72D4A-5417-4889-BE35-670E79EDE9EBQ38815279-2E536CBD-4907-442C-8559-2662E5C8B38CQ38824034-EF45B336-EA38-4E86-A1BD-D35AAD77DC5DQ38951755-BF66CD51-544A-4115-A4E8-24436BFD5641Q39013056-C8824EB6-E632-401E-B9E5-056AB4C9C507Q39741688-E1182C5C-2298-4115-B24F-22598010AC87Q40536743-874A2B30-AB9A-47DA-A902-F8B9A4732A4EQ40838932-6614A80D-0637-41D8-A76C-C852272CDB79Q42643753-3664D791-1C1B-4698-96C7-1E5BF6D8C967Q45895265-BB6BFAB5-6A77-49DF-A9CC-5CD0B2B0C7ABQ48274043-50354722-5B2F-43BA-9E91-6A19B99F4BE7
P2860
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The association of the treatme ...... rospective observational study
@ast
The association of the treatme ...... rospective observational study
@en
type
label
The association of the treatme ...... rospective observational study
@ast
The association of the treatme ...... rospective observational study
@en
prefLabel
The association of the treatme ...... rospective observational study
@ast
The association of the treatme ...... rospective observational study
@en
P2093
P2860
P1476
The association of the treatme ...... rospective observational study
@en
P2093
David Maggs
Jennie H Best
Kerenaftali Klein
P2860
P2888
P356
10.1186/S12933-015-0178-3
P407
P577
2015-01-24T00:00:00Z
P5875
P6179
1044310783